{"filing":{"accession_number":"0001193125-26-234862","cik":"0001812364","ticker":"RLAY","company_name":"Relay Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"d128795d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526234862/d128795d8k.htm"},"events":[{"id":9435,"run_id":8274,"accession_number":"0001193125-26-234862","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Relay Therapeutics entered into an Underwriting Agreement on May 20, 2026, for an underwritten public offering of 22,916,667 shares at $12.00 per share, with underwriters exercising a full 30-day option for an additional 3,437,500 shares, generating approximately $296.8 million in net proceeds. This is a material registered equity issuance that dilutes existing shareholders and materially affects the company's capital structure and investor assessment.","company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1077,"accession_number":"0001193125-26-234862","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Relay Therapeutics entered into an Underwriting Agreement on May 20, 2026, for an underwritten public offering of 22,916,667 shares at $12.00 per share, with underwriters exercising a full 30-day option for an additional 3,437,500 shares, generating approximately $296.8 million in net proceeds. This is a material registered equity issuance that dilutes existing shareholders and materially affects the company's capital structure and investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:56:17.303567+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1077,"accession_number":"0001193125-26-234862","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Relay Therapeutics entered into an Underwriting Agreement on May 20, 2026, for an underwritten public offering of 22,916,667 shares at $12.00 per share, with underwriters exercising a full 30-day option for an additional 3,437,500 shares, generating approximately $296.8 million in net proceeds. This is a material registered equity issuance that dilutes existing shareholders and materially affects the company's capital structure and investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:56:17.303567+00:00","company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","filing_date":"2026-05-21"}]}